9.58
price down icon0.62%   -0.06
after-market Handel nachbörslich: 9.11 -0.47 -4.91%
loading

Cervomed Inc Aktie (CRVO) Neueste Nachrichten

pulisher
Nov 20, 2024

CRVO (CervoMed) EV-to-Revenue : (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 19, 2024

CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St

Nov 19, 2024
pulisher
Nov 18, 2024

CervoMed shares coverage initiated with buy rating on DLB drug potential - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

CervoMed initiated with a Buy at D. Boral Capital - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

D. Boral Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN

Nov 18, 2024
pulisher
Nov 16, 2024

CervoMed Inc. (NASDAQ:CRVO) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

CervoMed FY2024 EPS Lowered by Brookline Capital Management - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

AWM Investment Company, Inc. Expands Stake in CervoMed Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

CervoMed appoints Ordonez, Rosch as SVPs - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

CervoMed bolsters leadership for neurologic drug development By Investing.com - Investing.com Nigeria

Nov 13, 2024
pulisher
Nov 13, 2024

CervoMed bolsters leadership for neurologic drug development - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

CervoMed Announces Key Senior Leadership Appointments - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

CervoMed Bolsters Leadership Team Ahead of Crucial Lewy Body Dementia Drug Trial | CRVO Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

CervoMed Inc. (CRVO) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

CervoMed Inc. Announces Executive Appointments - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

CervoMed's Q3 Loss Widens to $4.8M Despite $46.7M Cash Reserve; Awaits Key Trial Data | CRVO Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - GlobeNewswire

Nov 08, 2024
pulisher
Nov 07, 2024

CervoMed to Participate in Upcoming Investor Conferences - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

CervoMed Announces Key Takeaways from Oral Presentations at - GlobeNewswire

Nov 04, 2024
pulisher
Nov 01, 2024

CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 7.6% in October - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

CervoMed (NASDAQ:CRVO) Shares Down 3.1% – Time to Sell? - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

CervoMed (NASDAQ:CRVO) Stock Price Down 3.1%What's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 30, 2024

CervoMed to Present Phase 2b Trial Results - TipRanks

Oct 30, 2024
pulisher
Oct 29, 2024

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference - GlobeNewswire

Oct 29, 2024
pulisher
Oct 18, 2024

Insiders of CervoMed Inc. (NASDAQ:CRVO) were rewarded after last week’s 11% gain - Simply Wall St

Oct 18, 2024
pulisher
Oct 15, 2024

CRVOCervoMed Inc. Latest Stock News & Market Updates - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

CervoMed Announces Last Patient Last Visit in Phase 2b - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - StockTitan

Oct 15, 2024
pulisher
Oct 04, 2024

CervoMed Ends $20 Million Stock Sales Agreement with BTIG - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

CervoMed ends sales agreement with BTIG By Investing.com - Investing.com South Africa

Oct 03, 2024
pulisher
Oct 03, 2024

CervoMed ends sales agreement with BTIG - Investing.com India

Oct 03, 2024
pulisher
Oct 02, 2024

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire

Oct 02, 2024
pulisher
Sep 30, 2024

CervoMed Inc. (NASDAQ:CRVO) Short Interest Update - MarketBeat

Sep 30, 2024
pulisher
Sep 26, 2024

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times

Sep 26, 2024
pulisher
Sep 26, 2024

CervoMed to present on neflamapimod as DLB treatment at CTAD - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

CervoMed to Deliver Late-Breaking Oral Presentations at the - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Armistice Capital LLC Sells 94,363 Shares of CervoMed Inc. (NASDAQ:CRVO) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

There is no way Cerence Inc (CRNC) can keep these numbers up - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Credo Technology Group (NASDAQ:CRDO) Trading Up 3% - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Certara Inc (CERT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Sep 25, 2024
pulisher
Sep 25, 2024

Closing Figures Unveiled: Cemtrex Inc. (CETX) Drop -3.49, Closes at 0.14 - The Dwinnex

Sep 25, 2024
pulisher
Sep 25, 2024

Examining Certara Inc (CERT) more closely is necessary - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Cerence Inc. (CRNC)’s $40 Million Revenue Guidance Signals Trouble for Investors - Insider Monkey

Sep 25, 2024
pulisher
Sep 25, 2024

(CRVO) Technical Pivots with Risk Controls - Stock Traders Daily

Sep 25, 2024
pulisher
Sep 25, 2024

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Holdings of CERo Therapeutics Holdings Inc. (CERO) are aligned with the stars - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

CERo Therapeutics Holdings Inc. (CERO)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Sep 25, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):